Rather, JW Pharma's official position is that the total number of adverse events, including thromboembolism, is more than three times greater in factor VIII. JW Pharma issued a statement on the 22nd and refuted the press release distributed by GC Pharma the previous day (21st). GC Pharma participated in the Bleeding Disorders Conference and distributed a press release stating that "Hemlibra's thrombosis adverse event reporting rate was 2.8 times higher than factor VIII" based on the analysis results of adverse events reported in the FDA Adverse Event Reporting System. Factor VIII is a hemophilia treatment sold in Korea by GC Pharma and Hemlibra by JW Pharmaceutical. JW Pharmaceutical explained in the press release tha